Tourmaline Bio Statistics

Total Valuation

Tourmaline Bio has a market cap or net worth of $689.27 million. The enterprise value is $407.64 million.

Market Cap	689.27M
Enterprise Value	407.64M

Important Dates

The last earnings date was Thursday, November 7, 2024, before market open.

Earnings Date	Nov 7, 2024
Ex-Dividend Date	n/a

Share Statistics

Tourmaline Bio has 25.64 million shares outstanding. The number of shares has increased by 16.90% in one year.

Current Share Class	25.64M
Shares Outstanding	25.64M
Shares Change (YoY)	+16.90%
Shares Change (QoQ)	+0.17%
Owned by Insiders (%)	8.45%
Owned by Institutions (%)	54.07%
Float	12.55M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	2.15
P/TBV Ratio	2.15
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 40.33, with a Debt / Equity ratio of 0.00.

Current Ratio	40.33
Quick Ratio	38.70
Debt / Equity	0.00
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -31.82% and return on invested capital (ROIC) is -24.50%.

Return on Equity (ROE)	-31.82%
Return on Assets (ROA)	-23.82%
Return on Capital (ROIC)	-24.50%
Revenue Per Employee	n/a
Profits Per Employee	-$1.45M
Employee Count	44
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +64.91% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+64.91%
50-Day Moving Average	25.06
200-Day Moving Average	22.27
Relative Strength Index (RSI)	51.91
Average Volume (20 Days)	167,914

Short Selling Information

The latest short interest is 1.56 million, so 6.07% of the outstanding shares have been sold short.

Short Interest	1.56M
Short Previous Month	1.52M
Short % of Shares Out	6.07%
Short % of Float	12.41%
Short Ratio (days to cover)	6.39

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-78.82M
Pretax Income	-35.69M
Net Income	-63.88M
EBITDA	-78.78M
EBIT	-78.82M
Earnings Per Share (EPS)	-$2.79

Full Income Statement

Balance Sheet

The company has $281.92 million in cash and $290,000 in debt, giving a net cash position of $281.63 million or $10.98 per share.

Cash & Cash Equivalents	281.92M
Total Debt	290,000
Net Cash	281.63M
Net Cash Per Share	$10.98
Equity (Book Value)	321.07M
Book Value Per Share	12.52
Working Capital	286.50M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$65.73 million and capital expenditures -$2,000, giving a free cash flow of -$65.73 million.

Operating Cash Flow	-65.73M
Capital Expenditures	-2,000
Free Cash Flow	-65.73M
FCF Per Share	-$2.56

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Tourmaline Bio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-16.90%
Shareholder Yield	-16.90%
Earnings Yield	-9.27%
FCF Yield	-9.54%

Dividend Details

Analyst Forecast

The average price target for Tourmaline Bio is $65.00, which is 141.82% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$65.00
Price Target Difference	141.82%
Analyst Consensus	Strong Buy
Analyst Count	3
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	-27.14%

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1